D. Richard Francis's most recent trade in Teva- Pharmaceutical Industries Ltd. - ADR was a trade of 52,173 Restricted Share Units done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 52,173 | 52,173 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 169,811 | 169,811 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 50,223 | 295,556 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 50,223 | 150,669 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Sale of securities on an exchange or to another person at price $ 15.73 per share. | 04 Mar 2025 | 15,514 | 280,042 (0%) | 0% | 15.7 | 244,107 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Sale of securities on an exchange or to another person at price $ 15.91 per share. | 04 Mar 2025 | 8,259 | 271,783 (0%) | 0% | 15.9 | 131,427 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 67,231 | 276,675 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 67,231 | 134,462 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Sale of securities on an exchange or to another person at price $ 16.19 per share. | 03 Mar 2025 | 24,892 | 251,783 (0%) | 0% | 16.2 | 402,889 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Sale of securities on an exchange or to another person at price $ 15.56 per share. | 03 Mar 2025 | 6,450 | 245,333 (0%) | 0% | 15.6 | 100,347 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 161,655 | 284,950 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 161,655 | 161,656 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Sale of securities on an exchange or to another person at price $ 16.95 per share. | 15 Feb 2025 | 75,506 | 209,444 (0%) | 0% | 16.9 | 1,279,661 | Ordinary Shares |
| Mettler-Toledo International | Richard D. Francis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2024 | 182 | 182 | - | - | Stock Option (right to buy) | |
| Mettler-Toledo International | Richard D. Francis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2024 | 71 | 624 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2024 | 200,892 | 200,892 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 67,231 | 201,693 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 67,231 | 154,356 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard D. Francis | President and CEO | Sale of securities on an exchange or to another person at price $ 13.34 per share. | 03 Mar 2024 | 31,061 | 123,295 (0%) | 0% | 13.3 | 414,270 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Francis Richard D. | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 161,655 | 161,655 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | D. Richard Francis | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 161,655 | 323,311 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | D. Richard Francis | President and CEO | Sale of securities on an exchange or to another person at price $ 13.15 per share. | 15 Feb 2024 | 74,530 | 87,125 (0%) | 0% | 13.2 | 980,174 | Ordinary Shares |